Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma
Journal of Clinical Oncology, 05/02/2012Janne PA et al.
Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced non–small–cell lung cancer (NSCLC). EGFR mutations identify patients most likely to benefit.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.